Information Provided By: 
Fly News Breaks for March 31, 2015
HPTX, HZNP
Mar 31, 2015 | 07:47 EDT
Brean Capital believes Horizon Pharma's (HPZN) guidance on annualized cost savings from its deal with Hyperion Therapeutics (HPTX) is conservative. The firm noted Horizon executes well on M&A, as it paid a reasonable price for Hyperion. Brean Capital reiterated its Buy rating and raised its price target to $33 from $27 on Horizon Pharma shares.
News For HZNP;HPTX From the Last 2 Days
There are no results for your query HZNP;HPTX
